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ing and manufacturing appropriate paediatric drugs
(www.hivforum.org).
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Variant Creutzfeldt-Jakob disease: prion protein genotype
analysis of positive appendix tissue samples from a
retrospective prevalence study
James W Ironside, Matthew T Bishop, Kelly Connolly, Doha Hegazy, Suzanne Lowrie,
Margaret Le Grice, Diane L Ritchie, Linda M McCardle, David A Hilton
Abstract
Objective To perform prion protein gene (PRNP)
codon 129 analysis in DNA extracted from appendix
tissue samples that had tested positive for disease
associated prion protein.
Design Reanalysis of positive cases identified in a
retrospective anonymised unlinked prevalence study
of variant Creutzfeldt-Jakob disease (vCJD) in the
United Kingdom.
Study samples Three positive appendix tissue
samples out of 12 674 samples of appendix and tonsil
tested for disease associated prion protein. The
patients from whom these samples were obtained
were aged 20-29 years at the time of surgery, which
took place in 1996-9.
Setting Pathology departments in two tertiary centres
in England and Scotland.
Results Adequate DNA was available for analysis in
two of the three specimens, both of which were
homozygous for valine at codon 129 in the PRNP.
Conclusions This is the first indication that the valine
homozygous subgroup at codon 129 in the PRNP is
susceptible to vCJD infection. All tested clinical cases
of vCJD have so far occurred in the methionine
homozygous subgroup, and a single case of probable
iatrogenic vCJD infection has been identified in one
patient who was a methionine/valine heterozygote at
What is already known on this topic
The evidence base for prescribing drugs to
children lacks sufficient pharmacokinetic and
pharmacodynamic data
Adult doses are often extrapolated to children
without taking account of potential differences in
drug handling with age or dose requirements for
effectiveness
Licensing data for paediatric dosing are often
sparse, and subsequent studies may result in
important changes to recommended doses
What this study adds
HIV infected UK and Irish children have been
underdosed with antiretrovirals in the past nine
years
Poor pharmacokinetic data at licensing results in
incorrect drug dosing until important
pharmacokinetic results emerge after licensing
and inform revision of dosage recommendations
Guidelines stating alternative dosage strategies (by
weight or surface area) for the same drug lead to
different and inconsistent doses
Inadequate dosing also arises through failure to
adjust for ongoing growth
This article was posted on bmj.com on 10 April 2006:
http://bmj.com/cgi/doi/10.1136/bmj.38804.511644.55
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this genetic locus. People infected with vCJD with a
valine homozygous codon 129 PRNP genotype may
have a prolonged incubation period, during which
horizontal spread of the infection could occur either
from blood donations or from contaminated surgical
instruments used on these individuals during the
asymptomatic phase of the illness.
Introduction
In a prevalence study for variant Creutzfeldt-Jakob
disease (vCJD), we identified three appendixes that
stained positively for disease associated prion protein
(PrP). We looked at 12 674 specimens (11 109 appendi-
ces, 1565 tonsils) removed from 1995-2000. Most of the
patients (83%) were aged 10-30 years at the time of
operation.1 2 This number of positive results is greater
than would be predicted from the numbers of patients
diagnosed with vCJD in the United Kingdom (161 to
date). Furthermore, the annual incidence of new cases of
vCJD has declined from a peak in 1999. As all patients
with vCJD belong to the methionine homozygous
subgroup, determined by the codon 129 polymorphism
in the prion protein gene (PRNP),2 one possible
explanation for this apparent discrepancy could be a
different PRNP genotype in the three positive cases (the
prevalences of PRNP codon 129 genotypes in the
general UK population are about 40% methionine
homozygous, 10% valine homozygous, and 50% hetero-
zygous). This possibility was supported by a slightly
different pattern of immunoreactivity in the second and
third positive appendix cases in comparison with clinical
cases of vCJD.2 We recently identified a case of asympto-
matic vCJD infection that seemed to have been
transmitted by red cell transfusion in a PRNP codon 129
heterozygote, demonstrating that the methionine
homozygous genotype is not uniquely susceptible to
vCJD infection.3
Methods
We analysed the PRNP codon 129 polymorphism in the
three samples of appendix tissue embedded in paraffin
that stained positively for disease associated prion
protein in the prevalence study. In the first case, a trans-
mission study is currently under way usingmaterial from
the remaining unstained sections. This meant that only
immunostained sections were available for genotype
studies and the extracted DNAwas not good enough for
further analysis. In the two remaining cases, as there was
not sufficient material available for both transmission
studies and genotype studies, and in view of possible
PRNP influences on the staining pattern of disease asso-
ciated prion protein in these cases, we used the remain-
ing material for DNA analysis. A single 6 m unstained
paraffin section was available from each case, and these
were de-paraffinised and scraped into individual micro-
centrifuge tubes for DNA extraction with the Puregene
DNA Purification Kit (Gentra Systems, USA). Pelleted
DNA was rehydrated for one hour at 65°C and then
used as a template for amplification by the polymerase
chain reaction (PCR), along with positive and negative
control samples. PCR primers used were specific for a
506 bp region of PRNP containing the polymorphic
sequence for the codon 129 residue. PCR products were
digested at 37°C with the restriction enzyme Nsp1 (New
England Biolabs, UK), which specifically recognises
changes at the PRNP codon 129 polymorphic DNA
sequence. Digest products were analysed on 1.5%
agarose gels with positive controls for the codon 129
variants (MV, VV, and MM).
Results
For both cases the genotype was confirmed as
homozygous for the valine allele (VV) (figure). This
method has been previously validated4 5 and was
controlled in our laboratory by studying the PRNP
codon 129 genotype in both paraffin embedded
sections and frozen tissues from 25 other cases.
Discussion
These results give the first indication that PRNP codon
129 valine homozygotes may be susceptible to vCJD
infection. Though the immunohistochemical tech-
nique used in our earlier study seems to be specific for
disease associated prion protein,6 it is unlikely to be
100% sensitive, suggesting that the true prevalence of
vCJD infection in the UK population may be even
higher than earlier estimated (3/12 674).2 Genetic
studies of kuru, another orally transmitted human
prion disease, found that PRNP codon 129 MV and
VV genotypes were associated with longer incubation
periods than the MM genotype.7 As the ethical
approval for our study placed restraints on the identifi-
cation of individual cases, we are not able to state with
certainty the age of the patients in the positive cases at
the time of surgery. We can, however, state that they
were aged 20-29 years at the time of surgery, which
took place in 1996-9. No clinical cases of vCJD at any
age have yet been identified in PRNP codon 129 valine
homozygotes, indicating the need for continued
surveillance of all cases of vCJD in the UK.
Restriction digest pattern for PRNP codon 129 genotype analysis in two paraffin section tissue samples (shown combined). The test sample
results clearly show banding patterns equivalent to the VV genotype control (Mol=molecular weight ladder, N=PCR negative control,
Ap1=appendix tissue from positive case 2, Ap2=appendix tissue from positive case 3, positive control samples from PRNP codon 129 MV, VV,
and MM genotypes)
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Though it is inadvisable to overinterpret the data
from only three positive cases in this study, it is perhaps
surprising (given the relative prevalences of PRNP
codon 129 genotypes in the general population) that
both the positive cases analysed here were valine
homozygotes. Though this may represent a chance find-
ing, we should consider the possibility of differences in
the peripheral pathogenesis of vCJD that depend on the
PRNP codon 129 genotype. The patient who developed
asymptomatic vCJD infection after red blood cell trans-
fusion was a codon 129 heterozygote in whom both
tonsil and appendix tissues were negative on staining for
disease associated prion protein with identical methods
as used in this study, though the spleen and lymph
nodes gave positive results.3 PRNP polymorphisms in
sheep infected with scrapie also have a major influence
on the incubation period and timing and distribution of
disease associated prion protein in lymphoid tissues
during the incubation period.8
A prolonged incubation period after infection with
vCJD is likely to result in an asymptomatic carrier state
(which cannot yet be identified), which represents a
potential risk for horizontal transmission of vCJD
infection by blood transfusion, blood products, or con-
taminated surgical instruments. These uncertainties
further underline the need for continued surveillance
of vCJD in the UK (including surveillance for subclini-
cal or asymptomatic infection9), a requirement to con-
tinue to reduce the possibility of secondary iatrogenic
transmission, and the inclusion of carrier states and
susceptibility to vCJD infection in all PRNP codon 129
genotypes in future disease modelling.
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What is already known on this topic
A recent prevalence study of accumulation of prion protein (as a
marker for vCJD infection) in appendix and tonsil specimens in the
UK found 3/12 674 positive cases, which is more than expected from
the current number of clinical cases of vCJD
What this study adds
Analysis of DNA from two of the three positive samples found them to
be valine homozygotes at codon 129 in the prion protein gene,
indicating that this genetic subgroup (which is a different subgroup from
that in which all cases of vCJD have so far occurred) is susceptible to
vCJD infection
Individuals with this genotype may have a prolonged incubation
period with subclinical infection and could cause secondary spread of
vCJD by blood transfusion or surgery
Prescribing for RITA
And so it ends—a decade in the training grade. The last rites
performed with a final RITA (record of in training assessment):
I’m finally grown up, the authorities deem. In fact, my consultant
job starts tomorrow.
After 10 years with it, do I have positive suggestions for
postgraduate training in the NHS? Of course, dozens, most
involving workforce, reorganisation, and resources. But, as in life,
the best tonics are free. I vote for a fresh culture that values and
grows people. It is remarkable that NHS doctors deliver their
high quality service for no immediate tangible gain. More
extraordinary is that this work receives not a trace of the positive
feedback and moral incentive that would be critical to the health
of any comparable organisation.
I worked for some time in a prestigious institution of a more
advanced healthcare system. What made their people tick? True,
they had impressive buildings, state of the art technology, and
good salary prospects; but, really, I think they were primarily
driven by an ethos that valued excellence and individuality—
initiated, fostered, and rewarded it. Right down to the artwork that
lined the corridors—oversized portraits of the previous month’s
star employees, proud pictures of “graduating” trainees, plaques
of senior faculty.
A bit over the top perhaps, but preferable to the anonymous
passage of generations of juniors through Britain’s many worthy
hospitals. In addition, attitudes of derision towards the less skilled
and suspicion of those who seem too good or creative are all too
common. The end result? Blunted clones coming off an assembly
line: competent, yes; extraordinary, no. Tragic for individuals and
undesirable for a healthcare system that confronts extraordinary
problems.
There, I’ve had my shout. Tomorrow I step into a new world,
recognising that to change it is to change myself. I will not forget
my morning dose of free tonic.
Giridhar P Kalamangalam specialist registrar in neurology, Institute
of Neurological Sciences, Southern General Hospital, Glasgow
(g_kalamangalam@hotmail.com)
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